Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP435953.RAf5TVuvRsBT7gHNXi3wfPBogzItJtjCjLlEbkBvzLGys130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP435953.RAf5TVuvRsBT7gHNXi3wfPBogzItJtjCjLlEbkBvzLGys130_assertion type Assertion NP435953.RAf5TVuvRsBT7gHNXi3wfPBogzItJtjCjLlEbkBvzLGys130_head.
- NP435953.RAf5TVuvRsBT7gHNXi3wfPBogzItJtjCjLlEbkBvzLGys130_assertion description "[After 21 days, the tumors were excised, lymph node and lung metastases were quantified, and the hypoxic fraction and relative vascular area of the primary tumors were assessed by immunohistochemical staining for the hypoxic marker drug EF5 [2-(2-nitro-1H-imidazole-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] and the vascular marker CD31, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP435953.RAf5TVuvRsBT7gHNXi3wfPBogzItJtjCjLlEbkBvzLGys130_provenance.
- NP435953.RAf5TVuvRsBT7gHNXi3wfPBogzItJtjCjLlEbkBvzLGys130_assertion evidence source_evidence_literature NP435953.RAf5TVuvRsBT7gHNXi3wfPBogzItJtjCjLlEbkBvzLGys130_provenance.
- NP435953.RAf5TVuvRsBT7gHNXi3wfPBogzItJtjCjLlEbkBvzLGys130_assertion SIO_000772 15026343 NP435953.RAf5TVuvRsBT7gHNXi3wfPBogzItJtjCjLlEbkBvzLGys130_provenance.
- NP435953.RAf5TVuvRsBT7gHNXi3wfPBogzItJtjCjLlEbkBvzLGys130_assertion wasDerivedFrom befree-2016 NP435953.RAf5TVuvRsBT7gHNXi3wfPBogzItJtjCjLlEbkBvzLGys130_provenance.
- NP435953.RAf5TVuvRsBT7gHNXi3wfPBogzItJtjCjLlEbkBvzLGys130_assertion wasGeneratedBy ECO_0000203 NP435953.RAf5TVuvRsBT7gHNXi3wfPBogzItJtjCjLlEbkBvzLGys130_provenance.